Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer

Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer

Dec 30, 2019
|
staff reporter

NEW YORK – Eli Lilly said on Monday that its Phase III, LIBRETTO-531 clinical trial is

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Drug Discovery & Development

  1. Novartis Melanoma Triplet Therapy Failure Raises Questions for Other Combos; Subgroups May Benefit

    Premium

  2. FDA Expands Patient Access to BioMed Valley's ERK Inhibitor

  3. Relay Therapeutics Uses Protein Motion Simulation to Develop Highly Selective Precision Cancer Drugs

    Premium

  4. Growing Data on Vitrakvi Demonstrate Enduring Activity Across Variety of NTRK-Positive Tumor Types

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.